Business
Grant of Share Options to Chief Executive Officer
Shield Therapeutics PLC announced on October 13, 2025, the grant of share options to its Group CEO, Anders Lundstrom, under the company's Retention and Performance Share Plan (RPSP) as part of his 2025 annual equity grant. Lundstrom, a person discharging managerial responsibility, received options over 1,547,262 ordinary shares. These options vest in three equal tranches over three years from the grant date, contingent on his continued employment. The option awards represent approximately 0.1% of the total number of AIM securities currently in issue. The exercise price for these options is 1.5 pence per share. Lundstrom currently holds 585,000 ordinary shares in the company. Disclaimer*
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nGrant of Share Options to Chief Executive Officer\n \nLondon, UK, 14 October 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 13 October 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company (\"Ordinary Shares\") under Shield Therapeutics' Retention and Performance Share Plan (\"RPSP\") to the Group CEO as part of his 2025 annual equity grant. \nIn accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to Anders Lundstrom, Chief Executive Officer, who is deemed a PDMR:\n\n\n\n\nName\n\n\nOption Plan\n\n\nNumber of Ordinary Shares under Option\n\n\nVesting Date\n\n\n\n\nAnders Lundstrom\n\n\nRPSP\n\n\n1,547,262\n\n\nThree equal traches over three years from the date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting.\n\n\n\n\n \nThe proportion of total option awards to Anders Lundstrom is approximately 0.1% of the total number of AIM securities in issue at this time.\nAnders Lundstrom currently holds 585,000 ordinary shares in the Company.\n \n\n\n\n\n1.\n\n\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\n\n\n\n\na)\n\n\nName\n\n\nAnders Lundstrom\n\n\n\n\n2.\n\n\nReason for the notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nChief Executive Officer\n \n\n\n\n\nb)\n\n\nInitial notification/\namendment\n\n\nInitial Notification\n\n\n\n\n3.\n\n\nDetails of the Issuer\n\n\n\n\na)\n\n\nName\n\n\nShield Therapeutics plc\n\n\n\n\nb)\n\n\nLEI code\n\n\n213800G74QWY15FC3W71\n\n\n\n\n4.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na)\n\n\nDescription of the financial instrument\n \nIdentification code\n\n\nOptions over new Ordinary Shares\n \n \nISIN: GB00BYV81293\n\n\n\n\nb)\n\n\nNature of the transaction\n\n\nGrant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan.\n\n\n\n\nc)\n\n\nPrice(s) and volumes(s)\n\n\n2025 RPSP Award...